Advances in management of nonvariceal upper gastrointestinal bleeding

Holzwanger, Erik; Mahmoud, Mohamed; Wassef, Wahid

doi:10.1097/mog.0000000000000487

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 15 , 16 ] Thus, the current management of NUGIB aims to stabilize hemodynamic circulation, stop existing bleeding, and prevent its recurrence. [ 17 – 22 ]…”

Section: Introductionmentioning

confidence: 99%

“…[15,16] Thus, the current management of NUGIB aims to stabilize hemodynamic circulation, stop existing bleeding, and prevent its recurrence. [17][18][19][20][21][22] Endoscopic hemostatic intervention is reported that it cannot only identify high-risk stigmata on ulcers, but also can help control gastrointestinal bleeding to prevent its rebleeding and to decrease its mortality and morbidity. [23][24][25][26] However, there are still some patients who suffer from rebleeding accident.…”

Section: Introductionmentioning

confidence: 99%

“…It is reported that its 30-day mortality rate ranges from 5% to 10% [15,16] . Thus, the current management of NUGIB aims to stabilize hemodynamic circulation, stop existing bleeding, and prevent its recurrence [17–22] …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Study on the preventive effect of intravenous esomeprazole in the management of nonvarices upper gastrointestinal bleeding

Sun¹,

Yuan²,

Ma³

et al. 2021

Medicine

View full text Add to dashboard Cite

This retrospective study investigated the preventive effect of intravenous esomeprazole (IVEO) in the prevention of nonvarices upper gastrointestinal bleeding (NUGIB). This study enrolled 130 patients with NUGIB and all of them underwent successful endoscopic hemostasis, of which 65 cases received routine management and IVEO (Group A) and the other 65 cases received routine management alone (Group B). The primary outcome (recurrent bleeding rate within 72-hour, 7-day, and 30-day), and secondary outcomes ((all-cause mortality, bleeding-related mortality, blood transfused, hospital stay (day), and incidence of adverse events)) were compared between 2 groups. Patients in the group A showed lower recurrent bleeding rate within 72-hour( P < .05), 7-day ( P < .05), and 30-day ( P < .05), than that of patients in the group B. However, no significant differences were identified in all-cause mortality( P = .26), bleeding-related mortality ( P = .57), blood transfused ( P = .33), and hospital stay ( P = .74) between 2 groups. In addition, both groups had similar safety profile. This study found that routine management and IVEO was superior to the routine management alone for preventing the recurrent bleeding rate after successful endoscopic hemostasis in patients with NUGIB.

show abstract

“…[ 15 , 16 ] Thus, the current management of NUGIB aims to stabilize hemodynamic circulation, stop existing bleeding, and prevent its recurrence. [ 17 – 22 ]…”

Section: Introductionmentioning

confidence: 99%